Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance
Source: SeekingAlpha
2025-07-15 16:49:34 ET
More on Biodexa Pharmaceuticals
- Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals
- Historical earnings data for Biodexa Pharmaceuticals
- Financial information for Biodexa Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance
Biodexa Pharmaceuticals PLC-ADR
NASDAQ: BDRX
BDRX Trading
1.87% G/L:
$0.9499 Last:
43,117 Volume:
$0.95 Open:
BDRX Latest News
March 09, 2026 08:30:00 am
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
February 19, 2026 07:30:00 am
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
February 04, 2026 08:30:00 am
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
January 05, 2026 08:30:00 am
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
BDRX Stock Data
$2,864,159
2,232,691
1.2%
10
N/A
Biotechnology & Life Sciences
Healthcare
GB
Cardiff
